Financial Results for Quarter and Year ended on March 31, 2026

Emphasis of matterProfit growth above 25%Exceptional itemContingent liabilities increasedDebt to equity above the thresholdResults View source PDF Explain this filing

KRSNAA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹550.00

prior close

₹622.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-2.2% vs market

Healthcare Service Provider peers, median of 24sector-1.3%-0.1% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-7.9

10m

-9.7

15m

-8.8

30m

-8.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.7-2.2-1.3-0.1

Next day

-1.8+0.7-2.5+1.3-3.1

+0.0+0.0-0.0+1.2-1.2

-1.7-1.1-0.6-1.3-0.4

-0.5+0.0-0.5-1.2+0.7

-1.7+0.3-1.9-0.8-0.9

+0.5+1.1-0.6-1.3+1.8

15d

-2.5+4.9-7.4+1.6-4.2

-1.8+5.3-7.1-0.1-1.7

-1.4+6.9-8.3-4.2+2.8

+1.9+11.9-10.0+0.8+1.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Krsnaa Diagnostics reported audited standalone PAT of INR 1,026.75 million (FY26) vs INR 828.08 million (FY25), a growth of ~24%. Consolidated PAT grew stronger at INR 1,014.31 million vs INR 776.08 million, a ~30.7% increase. Standalone revenue from operations was INR 6,909.47 million (up 1.4% YoY) while consolidated revenue was INR 7,727.74 million (up 7.8%). The company recognized a one-time exceptional gain of INR 258.75 million from fair valuation of retained investment after ceasing significant influence over associate Apulki Healthcare. Finance costs increased significantly to INR 339.41 million (standalone) due to higher borrowings. Non-current borrowings surged to INR 4,371.44 million from INR 185.04 million, largely due to debenture issuance. The board recommended a final dividend of INR 2 per share (40% face value).

Likely market impact

Strong PAT growth driven by exceptional gain and operational improvement. The massive increase in borrowings raises leverage concerns. Pending tax demand of INR 626.90 million and proposed auditor change require monitoring.